Paper Details

  1. Home
  2. Paper Details

Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.

Author: AkamatsuShusuke, InoueTakahiro, KambaTomomi, KamotoToshiyuki, KawakitaMutushi, MatsuiYoshiyuki, OgawaOsamu, OguraKeiji, SegawaTakehiko, SuginoYoshio, TanakaShiro, TsukinoHiromasa, YamasakiToshinari

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Low-dose estramustine phosphate (EMP) was found to be a safe and effective treatment option for patients with castration-resistant prostate cancer.
Paper Details　
Original Abstract of the Article :
Despite the favorable toxicity profile at the standard dose of 560 mg daily, the tolerability and toxicology of estramustine phosphate (EMP) have been a cause for concern at administration. Moreover, we do not know whether a lower dose of 280 mg of EMP daily can be administered with some efficacy an...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clgc.2015.08.008

データ提供：米国国立医学図書館（NLM）

Low-Dose Estramustine Phosphate: A Safe and Effective Option for Prostate Cancer

This research, like a camel uncovering a hidden spring in the vast desert of [prostate cancer] treatment, investigates the safety and efficacy of [low-dose estramustine phosphate (EMP)] in patients with [castration-resistant prostate cancer]. The study explores the potential of a lower dose of EMP to achieve comparable efficacy with fewer side effects, offering a potentially more tolerable treatment option for patients battling this challenging disease.

Low-Dose Estramustine Phosphate: A Promising Alternative

This research suggests that [low-dose estramustine phosphate (EMP)] may be a safe and effective treatment option for patients with [castration-resistant prostate cancer]. The study found that low-dose EMP achieved comparable efficacy to the standard dose, indicating that it might be a viable alternative for patients who experience significant side effects with the higher dose. This research adds to the growing body of knowledge about the potential of personalized medicine and tailored treatment approaches in oncology.

Navigating the Desert of Prostate Cancer Treatment

As a camel traversing the desert of [prostate cancer] treatment, I find this research to be particularly encouraging. It highlights the potential of a new path in treating this challenging disease, suggesting that lower doses of EMP might offer a better balance of efficacy and tolerability for some patients.

Dr. Camel's Conclusion

This study, like a well-worn path through a challenging desert, provides hope for patients with castration-resistant prostate cancer. It suggests that low-dose estramustine phosphate might offer a safer and more tolerable treatment option, paving the way for personalized medicine and improved outcomes in prostate cancer management.
Date :
  1. Date Completed 2016-10-05
  2. Date Revised 2021-11-22
Further Info :

Pubmed ID

26433627

DOI: Digital Object Identifier

10.1016/j.clgc.2015.08.008

Related Literature

Article Analysis
・Side Effects of estramustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.